Komori
Other Disclosures4575CanBas Co.,Ltd.Pharmaceuticals

Notice of Receipt of Approval to Initiate a European Phase 3 Clinical Trial of CBP501

The Company received approval from the European Medicines Agency to initiate a Phase 3 clinical trial of the anticancer drug candidate CBP501 for third-line treatment of pancreatic cancer. The trial is scheduled to begin at sites in each country once the required procedures have been completed, followed by subject enrollment.

Worth reading
65In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
180
people (total for 2 groups; planned enrollment is approximate)
Wording
Conditional
How definitive the wording is.

Announced details

CBP501 (anticancer drug candidate compound and immune activator)
Applicable field (uses covered by this announcement)

Third-line treatment for pancreatic cancer

Launch dateOnce the required procedures with the authorities in each country have been completed, site activation and subject enrollment are scheduled to begin sequentially. Trial completion is expected in the first half of 2029.
Relationship between the counterparty and the company
CanBas Co.,Ltd.4575
Relationship with the Company

Relationship involving receipt of approval to initiate a Phase 3 clinical trial of CBP501 developed by the Company

CounterpartyEuropean Medicines Agency (EMA)

European Medicines Agency (EMA)

Awarding / certifying body

European Medicines Agency (EMA)

Location (as indicated in this announcement)

8 countries, approximately 50 sites (planned)

8 countries, approximately 50 sites (planned); approximately 180 subjects in total across 2 groups
Impact on Business Performance

The impact on current-period results is expected to be minor, although depending on progress going forward, results may vary due to factors including an increase in development expenses.

The company does not address Contract Value / Offering price.

Source (materials cited by the company)

Clinical Trials Information System (CTIS)

Announced details
ItemDetails
Names of Products / Services CoveredCBP501 (anticancer drug candidate compound and immune activator)
CounterpartyEuropean Medicines Agency (EMA)
Counterparty overviewEuropean Medicines Agency (EMA)
Relationship with the CompanyRelationship involving receipt of approval to initiate a Phase 3 clinical trial of CBP501 developed by the Company
Launch dateOnce the required procedures with the authorities in each country have been completed, site activation and subject enrollment are scheduled to begin sequentially. Trial completion is expected in the first half of 2029.
Applicable areaThird-line treatment for pancreatic cancer
Awarding / certifying bodyEuropean Medicines Agency (EMA)
Location8 countries, approximately 50 sites (planned)
Location scale8 countries, approximately 50 sites (planned); approximately 180 subjects in total across 2 groups
Impact on Business PerformanceThe impact on current-period results is expected to be minor, although depending on progress going forward, results may vary due to factors including an increase in development expenses.
SourceClinical Trials Information System (CTIS)
Items this document does not state (7)
Contract ValueOffering priceContract DateAward/certification nameRegistration number and expiry dateQuantitative EffectsUsage history

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The Company received approval from the European Medicines Agency to initiate the Phase 3 clinical trial. It explained that the expected timing of trial completion could vary significantly depending on the trial start date, the pace of subject enrollment and the time required for the interim analysis.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Receipt of Approval to Initiate a European Phase 3 Clinical Trial of CBP501 | CanBas Co.,Ltd. (4575) timely disclosure | Komori